Summit Therapeutics Inc.
SMMT
Clasificación en acciones
#1720
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Precio por acción
$15.56
Capitalización bursátil
$12.41B
Cambio (1 día)
6.36%
Cambio (1 año)
-25.87%
País
US
Comercio Summit Therapeutics Inc. (SMMT)
Categoría
Healthcare
Margen Operativo de Summit Therapeutics Inc. (SMMT)
Margen Operativo al October 2026 TTM: 0.00%
Según los informes financieros más recientes y el precio de las acciones de Summit Therapeutics Inc., el margen operativo actual (TTM) es 0.00%. Al final de 2023, el margen operativo era 0.00%.
Historial de Margen Operativo de Summit Therapeutics Inc. desde 2004 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -8,467.05% | 77.72% |
| 2021 | -4,764.29% | -22.97% |
| 2020 | -6,185.23% | 67.28% |
| 2019 | -3,697.51% | 1,669.40% |
| 2018 | -208.97% | -80.63% |
| 2017 | -1,078.65% | -51.91% |
| 2016 | -2,243.17% | 165.64% |
| 2015 | -844.44% | 73.06% |
| 2014 | -487.96% | 93.39% |
| 2013 | -252.32% | 48.37% |
| 2012 | -170.06% | -78.12% |
| 2011 | -777.38% | -74.49% |
| 2010 | -3,047.57% | -57.67% |
| 2009 | -7,198.87% | 1,753.18% |
| 2008 | -388.46% | -8.34% |
| 2007 | -423.82% | 25.04% |
| 2006 | -338.96% | 34.29% |
| 2005 | -252.40% | -89.48% |
| 2004 | -2,400.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.